Ateganosine

Financing included participation by healthcare-dedicated investors alongside existing shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.50 per share for aggregate gross proceeds of $30 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on March 4, 2026, subject to satisfaction of customary closing conditions. The offering was structured as a straightforward common stock only investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders. Konik Capital Partners, LLC, a division of T.R. Winston & Company is acting as the sole book-running manager for the offering. MAIA intends to use the net proceeds from the offering to conduct clinical trials and for working capital and general corporate purposes. The securities described above are being offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-273984), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 15, 2023, and declared effective on August 23, 2023. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement.. A prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to this offering have been filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, on the SEC’s website at or by contacting Konik Capital Partners LLC, a division of T.R. Winston & Company, at 7 World Trade Center, 46th Floor, New York, NY 10007, Attention: Capital Markets Team, Email: capmarkets@konikcapitalpartners.com . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About MAIA Biotechnology MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit . Cautionary Note Regarding Forward-Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended). Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates and (viii) the closing of our underwritten public offering of common stock, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. A detailed discussion of these uncertainties and risks that affect our business is contained in our SEC filings, including our reports on Form 10-K and Form 10-Q, particularly under the heading “Risk Factors.” Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries. Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com

Ongoing Phase 3 full approval clinical trial of ateganosine holds high 正在进行的阿特加诺星三期全面批准临床试验具有很高的价值probability of technical success for interim and full analysis 中期和完整分析的技术成功概率FDA Fast Track designation offers clear pathway for ateganosine as third-line therapy for non-small cell lung cancer (NSCLC) FDA快速通道资格为ateganosine作为非小细胞肺癌（NSCLC）的三线治疗提供了明确的途径。First and only direct telomere-targeting anticancer agent in clinical development anywhere 首个也是唯一一个处于临床开发阶段的直接靶向端粒的抗癌药物MAIA CEO details development pipeline in letter to shareholders MAIA首席执行官在致股东的信中详细介绍了开发流程CHICAGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- 芝加哥，2026年2月24日（环球新闻社）--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in clinical trials of its lead molecule, ateganosine, as a treatment for non-small cell lung cancer (NSCLC). MAIA生物技术公司（纽约证券交易所代码：MAIA）（“MAIA”，“公司”），一家专注于开发癌症靶向免疫疗法的临床阶段生物制药公司，今天发布了创始人兼首席执行官弗拉德·维托克医学博士致股东的2026年信函，重点介绍了其先导分子ateganosine在非小细胞肺癌（NSCLC）治疗临床试验中的强劲进展。As a potential breakthrough therapy, ateganosine holds substantial commercial opportunity in a $50 billion global immunotherapy market.. 作为一款潜在的突破性疗法，阿特加诺星在全球免疫治疗市场中拥有巨大的商业机会，该市场的规模达到500亿美元。1 1As stated in the Letter, Dr. Vitoc wrote, “Our development strategy intentionally targets the third-line (3L) NSCLC population, where the unmet need is urgent. No established standard of care exists in 3L treatment, with most oncologists currently treating 3L patients with chemotherapy, leading to particularly poor clinical outcomes. 正如信中所述，维托克博士写道：“我们的开发战略有意针对三线（3L）非小细胞肺癌（NSCLC）人群，那里的未满足需求十分迫切。在三线治疗中没有确立的标准治疗方法，目前大多数肿瘤医生使用化疗治疗三线患者，导致临床结果特别差。”In clinical studies, ateganosine sequenced with an immune checkpoint inhibitor (CPI) has demonstrated outcomes that exceed those historically achieved with either CPI-based therapy or chemotherapy alone. These findings position ateganosine not as a competitor to CPIs, but as the foundation of a new treatment category designed specifically for advanced NSCLC following CPI and chemotherapy failure. 在临床研究中，阿特加诺苷与免疫检查点抑制剂（CPI）序贯使用时，表现出超越历史上单独使用CPI疗法或化疗的疗效。这些研究结果表明，阿特加诺苷并非CPI的竞争者，而是成为一种全新治疗类别的基础，专为在CPI和化疗失败后的晚期非小细胞肺癌设计。By focusing on a third-line population with no defined standard of care, we are addressing an underserved group of approximately 50,000 patients annually in the United States and creating a differentiated, incremental revenue opportunity outside of the CPI market.. 通过关注没有明确护理标准的三线人群，我们正在解决美国每年约50,000名未被充分服务的患者的需求，并在CPI市场之外创造一个差异化、增量的收入机会。“Ateganosine could mark the start of a new therapeutic category in cancer treatment and could become the standard of care for multiple cancer indications,” Dr. Vitoc added. “The commercial opportunity for ateganosine could be immense.” “阿特加诺星可能标志着癌症治疗新疗法类别的开始，并可能成为多种癌症适应症的护理标准，”维托克博士补充道。“阿特加诺星的商业机会可能是巨大的。”Dr. Vitoc concluded his Letter with the following statement: “As we move forward, we are optimistic about the progress and potential outcomes of our advanced trials and the broader promise of ateganosine. We are grateful to our stockholders, employees, partners and investigators, for their continued support and commitment. 维托克博士在信中总结道：“展望未来，我们对高级试验的进展和潜在成果以及阿特加诺星的广阔前景感到乐观。我们感谢股东、员工、合作伙伴和研究人员的持续支持与承诺。”With strong momentum and a clear path ahead, we believe MAIA Biotechnology’s future is bright and rich with opportunity.”. 凭借强劲的发展势头和明确的前进道路，我们相信MAIA生物技术公司的未来是光明的，充满机遇。MAIA’s 2026 Letter to Shareholders is available in its entirety at MAIA致股东的2026年信函全文可在此处查阅：ir.maiabiotech.com ir.maiabiotech.com. 。About Ateganosine 关于AteganosineAteganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. Ateganosine（THIO、6-thio-dG 或 6-thio-2'-脱氧鸟苷）是一种首创的端粒靶向研究药物，目前正处于临床开发阶段，以评估其在非小细胞肺癌（NSCLC）中的活性。端粒以及端粒酶在癌细胞的存活及其对现有疗法的耐药性中发挥着关键作用。The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. 修饰核苷6-硫代-2'-脱氧鸟苷诱导端粒酶依赖性的端粒DNA修饰、DNA损伤反应和选择性癌细胞死亡。Ateganosine损伤的端粒片段在胞质微核中积累，并激活先天性（cGAS/STING）和适应性（T细胞）免疫反应。The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.. 阿特加诺星序贯PD-(L)1抑制剂治疗通过诱导癌症类型特异性免疫记忆，在晚期体内癌症模型中产生了深刻且持久的肿瘤消退。阿特加诺星目前正被开发用于非小细胞肺癌（NSCLC）的二线或后线治疗，针对那些已超出标准治疗方案（现有检查点抑制剂）的患者。About MAIA Biotechnology, Inc. 关于MAIA生物技术公司MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. MAIA 是一家专注于靶向治疗和免疫肿瘤学的公司，致力于开发和商业化具有新颖作用机制的潜在首创药物，旨在有意义地改善和延长癌症患者的生命。我们的主要项目是 ateganosine（THIO），这是一种潜在的首创癌症端粒靶向剂，目前正处于临床开发阶段，用于治疗端粒酶阳性的非小细胞肺癌（NSCLC）患者。For more information, please visit . 欲了解更多信息，请访问 。www.maiabiotech.com www.maiabiotech.com. 。Forward Looking Statements 前瞻性声明MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. MAIA警告称，本新闻稿中除历史事实陈述之外的所有陈述均为前瞻性陈述。前瞻性陈述受到已知和未知风险、不确定性以及其他可能导致我们或我们行业的实际结果、活动水平、表现或成就与这些陈述所预期的情况有重大差异的因素的影响。The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. “可能”、“也许”、“将”、“应该”、“能够”、“预期”、“计划”、“预期”、“相信”、“估计”、“预测”、“打算”、“未来”、“潜在”或“继续”等词语以及其他类似表达的使用，旨在识别前瞻性陈述。然而，这些词语的缺失并不意味着陈述不是前瞻性的。For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. 例如，我们关于以下事项的所有陈述：(i) 我们临床前和临床研究以及研发计划的启动、时间、成本、进展和结果，(ii) 我们将产品候选者推进至临床研究并成功完成这些研究的能力，(iii) 监管文件提交和获批的时间或可能性，(iv) 我们开发、制造和商业化我们的产品候选者并改进制造工艺的能力，(v) 我们产品候选者的市场接受速度和程度，(vi) 我们产品候选者市场的规模和增长潜力以及我们服务这些市场的能力，以及 (vii) 我们对我们获得并维持产品候选者知识产权保护能力的预期，均为前瞻性陈述。All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expr. 所有前瞻性声明均基于我们管理层的当前估计、假设和预期，尽管我们认为这些是合理的，但本质上存在不确定性。任何前瞻性声明表达。Investor Relations Contact 投资者关系联系人+1 (872) 270-3518 +1 (872) 270-3518ir@maiabiotech.com ir@maiabiotech.com1 1Immune Checkpoint Inhibitors Market Analysis by Mordor Intelligence, July 2025 Mordor Intelligence 免疫检查点抑制剂市场分析，2025年7月Released February 24, 2026 发布于2026年2月24日